The Comptroller General of the United States shall submit a report to Congress on the following:
(1)
The potential impact of nonprofit pharmaceutical organizations on the availability and cost of drugs, including on drug shortages, consumer costs, and costs to Federal programs.
(2)
The potential of nonprofit pharmaceutical organizations to accelerate development of new drugs, generic drugs, new biological products, biosimilar biological products, cell-based therapies, and devices.
(3)
Existing barriers to the success of nonprofit pharmaceutical organizations, including the ability of such organizations to obtain tax-exempt status, access to capital, and access to markets.
(4)
Potential actions by Congress that would allow nonprofit pharmaceutical organizations to deliver benefits to the pharmaceutical market.